Who
Jack A. Khattar
President, CEO
Company insider
Files Form 4 as: President, CEO, Supernus Pharmaceuticals; Director, Cognition Therapeutics; Director, scPharmaceuticals; President, CEO, Tesaro.
In numbers
- Trades disclosed
- 289
- Buys
- 4
- Sells
- 35
- Bought
- $296K
- Sold
- $41.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 4 May 2012
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —29,849 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $589K12,642 at $46.57 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —29,849 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —29,849 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —29,849 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $589K12,642 at $46.57 | filing |
| 29 Jul 2026filed 31 Jul 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —29,849 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —29,849 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code J | —12,500 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code J | —12,500 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.2M24,138 at $50.09 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $548K10,742 at $51.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $6,210120 at $51.75 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code J | —12,500 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code J | —12,500 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.2M24,138 at $50.09 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $548K10,742 at $51.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $6,210120 at $51.75 | filing |
News
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026SUPN · manilatimes.net · 19 Oct 2026Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026Shineco (NASDAQ:SISI) vs. Supernus Pharmaceuticals (NASDAQ:SUPN) Financial AnalysisSUPN · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Jack A. Khattar; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.